Your search for mepolizumab returned 61 results

The researchers conducted a retrospective cohort study using claims data from the Optum Research Database for 538 patients at least 6 years of age who initiated mepolizumab treatment for asthma between January 2016 and December 2019.

Trial enrolled children from disadvantaged urban neighborhoods who have exacerbation-prone eosinophilic asthma

What is the difference in efficacy between mepolizumab and benralizumab, 2 biologics approved for the treatment of severe eosinophilic asthma?

The phase 3 SYNAPSE clinical trial evaluated the efficacy of mepolizumab in improving sense of smell in patients with chronic rhinosinusitis with nasal polyps.

Mepolizumab reduces disease symptoms in patients with chronic rhinosinusitis with nasal polyps, according to the results of a randomized, double-blind, multicenter study.

The FDA previously granted Fast Track and Orphan Drug designations to mepolizumab for the treatment of HES.

Patients with severe eosinophilic asthma who are treated with mepolizumab and subsequently stop treatment have increased blood eosinophil counts and increased exacerbations, among other negative clinical outcomes.

Patients with severe eosinophilic asthma who are treated with mepolizumab and subsequently stop treatment have increased blood eosinophil counts and increased exacerbations, among other negative clinical outcomes.

Treatment with mepolizumab is associated with improvements in asthma exacerbation rates and health-related quality of life in patients with severe eosinophilic asthma and comorbid nasal polyps, sinusitis, or allergic rhinitis.

GlaxoSmithKline announced positive results from the pivotal phase 3 study of mepolizumab in the treatment of patients with hypereosinophilic syndrome (HES). HES is a rare group of inflammatory disorders characterized by persistent eosinophilia that can potentially lead to inflammation, organ damage, and possibly death if left untreated.  The 32-week, double-blind, placebo-controlled phase 3 study evaluated…